![Stock-Card](https://analystock-ai.s3.amazonaws.com/base/img/logo-analystock.png)
AI Spotlight on CDXC
Company Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging.The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services.It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function.It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries.The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.
ChromaDex Corporation is headquartered in Los Angeles, California.
Market Data
Last Price | 5.9 |
Change Percentage | 0.27% |
Open | 5.88 |
Previous Close | 5.88 |
Market Cap ( Millions) | 450 |
Volume | 6106 |
Year High | 7.97 |
Year Low | 1.46 |
M A 50 | 6.27 |
M A 200 | 4.14 |
Financial Ratios
FCF Yield | 0.88% |
Dividend Yield | 0.00% |
ROE | 4.85% |
Debt / Equity | 8.42% |
Net Debt / EBIDTA | -1516.08% |
Price To Book | 13.03 |
Price Earnings Ratio | 301.62 |
Price To FCF | 113.32 |
Price To sales | 4.46 |
EV / EBITDA | 216.25 |
News
- Jan -06 - ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
- Dec -24 - 4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
- Dec -09 - ChromaDex (CDXC) is on the Move, Here's Why the Trend Could be Sustainable
- Dec -03 - ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
- Nov -21 - Recent Price Trend in ChromaDex (CDXC) is Your Friend, Here's Why
- Nov -14 - ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement
- Nov -08 - What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now?
- Nov -08 - 5 Stocks With Recent Price Strength to Tap Wall Street Rally
- Nov -07 - ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
- Nov -05 - ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?
- Nov -05 - ChromaDex (CDXC) Is a Great Choice for 'Trend' Investors, Here's Why
- Nov -01 - ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
- Oct -31 - ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates
- Oct -29 - ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect
- Oct -28 - ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
- Oct -23 - ChromaDex to Participate in the 17th Annual LD Micro Main Event
- Oct -18 - Are Medical Stocks Lagging ChromaDex (CDXC) This Year?
- Oct -15 - Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
- Sep -26 - ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
- Sep -26 - Is ChromaDex (CDXC) Stock Outpacing Its Medical Peers This Year?
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Consumer Products
Expected Growth : 15 %
What the company do ?
ChromaDex Corporation's Consumer Products segment offers a range of healthy aging and wellness products, including Tru Niagen, a patented nicotinamide riboside (NR) supplement.
Why we expect these perspectives ?
ChromaDex Corporation's 15% growth in Consumer Products is driven by increasing demand for healthy aging and wellness products, particularly among the aging population. The company's proprietary Nicotinamide Riboside (NR) ingredient, a key component in its Tru Niagen supplement, is a major contributor to this growth. Additionally, expanding distribution channels, strategic partnerships, and a growing e-commerce presence also support the segment's rapid growth.
Segment n°2 -> Ingredients
Expected Growth : 12 %
What the company do ?
ChromaDex's Ingredients are proprietary, scientifically-backed, and patented ingredients, including Niagen, TRU NIAGEN, and others, designed to support healthy aging and wellness.
Why we expect these perspectives ?
ChromaDex Corporation's 12% growth is driven by increasing demand for healthy aging and wellness products, rising adoption of Tru Niagen, a proprietary nicotinamide riboside (NR) ingredient, and expansion into new markets. Additionally, growing awareness of the importance of nicotinamide adenine dinucleotide (NAD+) in energy metabolism and DNA repair is fueling demand for ChromaDex's ingredients.
Segment n°3 -> Analytical Reference Standards and Services
Expected Growth : 10 %
What the company do ?
Analytical Reference Standards and Services from ChromaDex Corporation provide authenticated and certified reference materials for quality control and analytical testing in the pharmaceutical, nutraceutical, and food industries.
Why we expect these perspectives ?
ChromaDex's Analytical Reference Standards and Services segment growth is driven by increasing demand for quality control in the pharmaceutical, nutraceutical, and food industries. Rising regulatory requirements, growing consumer awareness of product safety, and the need for precise analytical testing are key factors contributing to 10% growth.
Chromadex Corporation Products
Product Range | What is it ? |
---|---|
TRU NIAGEN | A proprietary nicotinamide riboside (NR) supplement that supports energy metabolism and overall health |
Immulina | A proprietary, patented, and clinically-tested beta-1,3-D glucan ingredient that supports immune system function |
pTeroPure | A proprietary, patented, and clinically-tested pterostilbene antioxidant supplement that supports heart health and cognitive function |
Nicotinamide Riboside (NR) | A vitamin B3 derivative that supports energy metabolism, mitochondrial function, and overall health |
ChromaDex External Sales | A range of proprietary, patented, and clinically-tested ingredients sold to third-party companies for use in their products |
ChromaDex Corporation's Porter Forces
Threat Of Substitutes
ChromaDex Corporation's products are highly specialized and unique, making it difficult for substitutes to emerge.
Bargaining Power Of Customers
While ChromaDex Corporation has a diverse customer base, some large customers may have bargaining power due to their significant purchasing volumes.
Bargaining Power Of Suppliers
ChromaDex Corporation has a diversified supplier base, reducing the bargaining power of individual suppliers.
Threat Of New Entrants
The nutritional supplement industry is highly competitive, and new entrants may emerge, posing a threat to ChromaDex Corporation's market share.
Intensity Of Rivalry
The nutritional supplement industry is highly competitive, with many established players, leading to a high intensity of rivalry.
Capital Structure
Value | |
---|---|
Debt Weight | 10.33% |
Debt Cost | 3.95% |
Equity Weight | 89.67% |
Equity Cost | 13.76% |
WACC | 12.74% |
Leverage | 11.52% |
ChromaDex Corporation : Quality Control
ChromaDex Corporation passed 7 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
Company | Rational |
---|---|
LGND | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which … |
YMAB | Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers … |
PTGX | Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable … |
ARDX | Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, … |
BYSI | BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
![Ligand Pharmaceuticals Logo](https://financialmodelingprep.com/image-stock/LGND.png)
Ligand Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
![Protagonist Therapeutics Logo](https://financialmodelingprep.com/image-stock/PTGX.png)
Protagonist Therapeutics
A-Score
1-Year Total Return ->
🥉
![BeyondSpring Logo](https://financialmodelingprep.com/image-stock/BYSI.png)
BeyondSpring
A-Score
1-Year Total Return ->
4
![Y-mAbs Therapeutics Logo](https://financialmodelingprep.com/image-stock/YMAB.png)
Y-mAbs Therapeutics
A-Score
1-Year Total Return ->
5
![ChromaDex Logo](https://financialmodelingprep.com/image-stock/CDXC.png)
ChromaDex
A-Score
1-Year Total Return ->
6
![Ardelyx Logo](https://financialmodelingprep.com/image-stock/ARDX.png)